MUC1 Oncoprotein Regulates Bcr-Abl Stability and Pathogenesis in Chronic Myelogenous Leukemia Cells
Authors:
- 15 December 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (24) , 11576-11584
Abstract
Chronic myelogenous leukemia (CML) results from expression of the Bcr-Abl fusion protein in hematopoietic stem cells. The MUC1 heterodimeric protein is aberrantly overexpressed in diverse human carcinomas. The present studies show that MUC1 is expressed in the human K562 and KU812 CML cell lines. The results show that MUC1 associates with Bcr-Abl through a direct interaction between the Bcr N-terminal region and the MUC1 cytoplasmic domain. Stable silencing of MUC1 decreased cytoplasmic Bcr-Abl levels by promoting Bcr-Abl degradation. Silencing MUC1 was also associated with decreases in K562 and KU812 cell self-renewal capacity and with a more differentiated erythroid phenotype. The results further show that silencing MUC1 increases sensitivity of CML cells to imatinib-induced apoptosis. Analysis of primary CML blasts confirmed that, as found with the CML cell lines, MUC1 blocks differentiation and the apoptotic response to imatinib treatment. These findings indicate that MUC1 stabilizes Bcr-Abl and contributes to the pathogenesis of CML cells by promoting self renewal and inhibiting differentiation and apoptosis. [Cancer Res 2007;67(24):11576–84]Keywords
All Related Versions
This publication has 53 references indexed in Scilit:
- Bcr‐Abl stabilizes β‐catenin in chronic myeloid leukemia through its tyrosine phosphorylationThe EMBO Journal, 2007
- MUC1 oncoprotein blocks nuclear targeting of c‐Abl in the apoptotic response to DNA damageThe EMBO Journal, 2006
- Abrogation of Heat Shock Protein 70 Induction as a Strategy to Increase Antileukemia Activity of Heat Shock Protein 90 Inhibitor 17-Allylamino-Demethoxy GeldanamycinCancer Research, 2005
- MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90Oncogene, 2005
- The development of imatinib as a therapeutic agent for chronic myeloid leukemiaBlood, 2005
- Human DF3/MUC1 carcinoma-associated protein functions as an oncogeneOncogene, 2003
- Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemiaOncogene, 2002
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor proteinCell, 1993
- The BCR gene encodes a novel serine/threonine kinase activity within a single exonCell, 1991